Bioelectronics Corp (BIEL)

[youngkim]

Yes, a lot of people agree with you. It's perplexing to consider why Actipatch, a product available in 32 countries worldwide, including affluent markets like the United States and Europe, only achieves sales of $25,000. The scope for its distribution and potential demand suggests that the issue lies with mismanagement rather than any other explanation. Every time I fly and glance at the vast expanse of homes below, I can't help but think that if even one of those households was aware of Actipatch, its sales would soar far beyond $25,000.